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Summary Nitric oxide (NO), a biologically active mediator generated in many cell types by the enzyme NO
synthase, may play an important role in cardiovascular toxicity that is frequently observed in cancer patients
during intravenous (i.v.) interleukin 2 (IL-2) therapy. The induction of NO synthase and the production of NO
seem to be involved in the pathogenesis of the vascular leakage syndrome, as well as in the regulation of
myocardial contractility. In the present study, we evaluated the pattern of plasmatic NO changes during
multiple cycles of continuous i.v. infusion (CIVI) of IL-2 in ten advanced cancer patients (five males, five
females, median age 59 years, range 33-67 years; eight affected by renal cell cancer and two affected by
malignant melanoma). The patients received IL-2 at 18 MIU m-2 day-' (14 cycles) or 9 MIU m-2 day-l
(seven cycles) for 96 h, repeated every 3 weeks. Interferon alpha (IFN a) was also administered subcutaneously
(s.c.) during the 3 week interval between IL-2 cycles. For each cycle, plasma samples were collected before
treatment (to), 24 h (t,), 48 h (t2), 72 h (t3) and 96 h (t4) after the start of IL-2 infusion, and 24 h after the end
of the cycle. NO concentration was determined spectrophotometrically by measuring the accumulation of both
nitrite and nitrate (after reduction to nitrite). The following observations may be drawn from data analysis: (1)
plasma nitrate +nitrite significantly raised during treatment (P =0.0226 for to vs t3), but statistical significance
was retained only when cycles administered with IL-2 18 MIU m-2 day-' are considered (P=0.0329 for to vs
t3; P =0.0354 for to vs t2 vs t4) (dose-dependent pattern); (2) during subsequent cycles a significant trend toward
a progressive increase of plasma nitrate+ nitrite levels, with increasing cumulative dose of IL-2, was observed
(linear regression coefficient r=0.62, P=0.0141 for to; r=0.80, P=0.0003 for tl; r=0.62, P=0.013 for t2;
r=0.69, P=0.045 for t3); (3) plasma nitrate+nitrite levels peaked earlier in subsequent cycles than in the first
cycle; (4) all patients experienced hypotension. The mean of the systolic blood pressure values was significantly
lower at the time of plasma nitrate+nitrite peak than at to (P=0.0004); (5) the two cases of grade III
hypotension occurred in patients with the higher mean and peak plasma nitrate+nitrite values. We conclude
that determination ofplasma nitrate +nitrite levels during CIVI IL-2 can usefully estimate, in a dose-dependent
pattern, the degree of peripheral vascular relaxation and capillary leakage associated with cytokine action,
clinically manifested as hypotension. However, isolated cardiac toxicity that continues to represent a relevant
problem during IL-2 therapy, does not appear to correlate with plasma nitrate +nitrite levels; therefore, further
studies are required to understand adequately the mechanisms underlying IL-2-induced cardiac toxicity.
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Immunotherapy with interleukin 2 (IL-2) demonstrated
clinical activity in the treatment of advanced renal cell
carcinoma (RCC) (Linehan et al., 1993) and malignant
melanoma (MM) (Balch et al., 1993). Unfortunately,
intravenous administration of IL-2 is associated with
relevant cardiovascular side-effects: hypotension, fluid reten-
tion including pulmonary oedema, myocardial ischaemia and
myocarditis (White et al., 1994; Osanto et al., 1988). Renal
and hepatic dysfunctions are also common (Margolin et al.,
1989). However, cardiovascular toxicity is the main dose-
limiting effect of IL-2 immunotherapy and evidence has been
growing that nitric oxide (NO) may contribute to determine it
(Ochoa et al., 1992; Miles et al., 1994). NO is a biologically
active mediator generated in many cell types by the enzyme
NO synthase. Both a constitutive and an inducible isoform of
this enzyme have been described. The former, expressed in
vascular endothelium and neuronal tissue, plays a key role in
modulating vascular tone and neurotransmission (Moncada
and Higgs, 1993). The latter can be induced by a number of
cytokines in different tissues (Hibbs et al., 1992). The
induction of NO synthase in vessel walls is responsible for
the vasodilation and resistance to vasoconstrictors character-
istic of septic shock (Wang et al., 1994; Kilbourn et al., 1995;
Meyer et al., 1994; Petros et al., 1994), as well as the
hypotension induced by cytokine therapy in cancer patients
(Miles et al., 1994). More recently, NO has also been shown
to be involved in the control of myocardial contractility
(Finkel et al., 1992; De Belder et al., 1993; Paulus et al.,
1994). High concentrations of NO, generated by the inducible
isoform of NO synthase, have been associated with impaired
myocardial performance in a number of inflammatory heart
diseases (De Belder et al., 1993).
As IL-2 plays a central role in cell-mediated immunity and
is the key factor for the induction of a complex network of
cytokines, one could suggest that IL-2-mediated NO
generation by inducible NO synthase may contribute to the
cardiac adverse effects observed during immunotherapy, as
well as to hypotension. The aim of this study was to
determine the pattern of plasma NO changes, measured as
plasma nitrate + nitrite values during a number of continuous
intravenous infusions (CIVI) of IL-2, and to look for
correlations with the cardiovascular toxic side-effects
observed.
Materials and methods
Patients
The study included ten patients (five men, five women;
median age 59 years, range 33 -67 years; eight affected by
RCC and two suffering from MM) treated at our institution
between December 1994 and May 1995. Patients affected by
histologically confirmed progressive unresectable or meta-
static RCC or MM were eligible for CIVI IL-2 therapy
provided the following criteria were met: Eastern Cooperative
Oncology Group (ECOG) performance status < 1; white
blood cell count >4 x 10 1-', platelet count > 100 x 109 1,
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Table I Patients' characteristics
Perform-
Patient ance
Age Tumour Site of Previous status
(years) Sex type disease treatment (ECOG)
CA 59 F RCC Lung, nodes Surgery, IFN-a 1
CG 60 F RCC Lung, nodes Surgery, IFN-a 1
AD 63 F RCC Bone Surgery, IFN-cx 1
BP 37 F RCC Bone Surgery 1
GB 57 M RCC Lung Surgery 0
PG 33 M MM Nodes Surgery 1
GA 41 F MM Bone, liver Surgery 1
PR 66 Ma RCC Nodes Surgery, IL-2 0
LA 71 Ma RCC - Surgery, IL-2 0
BE 59 Ma RCC Primary, nodes - 1
a Treated with half-dose IL-2 (i.e. 9 MU m-2 day-1). RCC, renal cell
cancer; MM, malignant melanoma.
haematocrit >30%; serum bilirubin, creatinine, prothrombin
time (PT) and partial thromboplastin time (PTT) within
normal range. Exclusion criteria included: current evidence of
severe cardiovascular disease; contraindications to the use of
pressor agents; need of corticosteroids for concomitant
disease; central nervous system metastases; and other
concurrent primary malignancy. Patients were scheduled to
receive multiple cycles of IL-2 by continuous i.v. infusion
(CIVI) at the dose of 18 MIU m-2 day-' for 96 h. A dose
reduction (9 MIU m-2 day-') of IL-2 was considered if there
was a suggestion of increased probability of cardiovascular
disease upon historical and/or cardiological examination, and
when treatment had to be administered in an adjuvant
setting. The RCC patients were treated following a sequential
IL-2/IFN-oa schedule (Besana et al., 1994), while the MM
patients were treated with chemotherapy (dacarbazine, cis-
platinum) plus tamoxifen, followed by immunotherapy (CIVI
IL-2 and subcutaneous IFNa) (Foppoli et al., 1995). The
complete list of patients is reported in Table I.
Interleukin 2 treatment
The daily dose of recombinant IL-2 (Proleukin, Chiron) was
diluted in 1000 ml of 5% glucose solution for 96 h by CIVI
through a central venous line using a volumetric pump.
Interleukin 2 infusion was discontinued until resolution ofthe
observed side-effect in the case of any grade III World Health
Organization (WHO) toxicity (WHO, 1979) (grade II for
serum creatinine); major arrhythmias (i.e. atrial fibrillation,
ventricular tachycardia); prolongation of PT >3 s over
baseline or PTT > 10 s over baseline; sepsis, dyspnoea,
weight gain > 10% of baseline; fever >40°C lasting for more
than 4 h. Recombinant IL-2 infusion had to be withdrawn
and patients excluded from the protocol when one of the
following toxicities occurred: documented myocardial ischae-
mia or cardiac failure; severe arrhythmias not promptly
reversible after IL-2 interruption and/or antiarrhythmic
therapy; any grade IV WHO toxicity; serum creatinine or
bilirubin that failed to return to grade I toxicity or less after
IL-2 interruption. During IL-2 infusion, heart rate, blood
pressure and body temperature were carefully monitored
every 2 h; daily recordings of the electrocardiogram (ECG),
body weight and diuresis were also obtained. Additional
monitoring included full blood counts and haematochemical
parameters, such as creatine kinase, transaminases and lactic
dehydrogenase. Hypotension was managed by 20% human
albumin i.v. infusions and, when severe, with discontinuation
of rIL-2 and administration of dopamine as a pressor agent
at the dose of 5 ,g kg-' min-m.
Cardiovascular monitoring
The following cardiovascular side-effects were considered
during IL-2 administration: grade III (a decrease of systolic
blood pressure >40 but <60 mmHg) and grade IV
hypotension (a decrease of systolic blood pressure
>,60 mmHg) with respect to basal values; ischaemic ECG
abnormalities; regional or diffuse left ventricular wall motion
abnormalities; major arrhythmias (i.e. atrial fibrillation;
ventricular tachycardia); pericardial effusion.
Plasma nitrate+ nitrite determination
For each treatment cycle, a 4 ml blood sample was obtained
at the following time points: immediately before treatment (to,
basal), after 24 h (t,), after 48 h (t2), after 72 h (t3), after 96 h
(t4, end of treatment), and 24 h after the end of CIVI IL-2
(t5). Each blood sample was centrifuged within 5 min from
collection and the plasma was stored at -80°C until assay.
NO release was determined spectrophotometrically by
measuring the accumulation of both nitrite and nitrate (the
latter after reduction to nitrite) in the plasma samples. For
nitrate reduction, samples were centrifuged at 1000 xg (for
15 min at room temperature), to remove cells and particles.
Nitrate was stechiometrically reduced to nitrite by incubation
of sample aliquots (100,l) in a 96-well microtitre plates
(Costar), for 3 h at 37°C, in the presence of 0.1 U ml-'
nitrate reductase (Boehringer-Mannheim), 50 gM NADPH
and 5 gM FAD (Sigma). When nitrate reduction was
complete, NADPH, which interfered with the following
nitrite determination, was oxidised with 10 U ml-' lactate
dehydrogenase and 10 mm sodium pyruvate (Sigma) for
15 min at 37°C. Nitrite was determined spectrophotometri-
cally by using the Griess reaction (Green et al., 1982)
(sulphanilamide 1 mM, hydrochloride acid 0.1 M, naphthyl-
ethylenediamine 1 mM). The absorbance was measured at
540 nm. Concentrations were determined by comparison with
a standard curve obtained with sodium nitrite in water.
Data management and statistics
Data are presented, if not otherwise specified, as
mean+standard error of mean (s.e.m.). Differences between
means were tested with one-way analysis of variance
(ANOVA) and with two-tailed Student's t-test for paired
data. Differences between proportions were assessed with
two-tailed x2 test for 2 x 2 tables or Fisher's exact test when
required. A linear regression coefficient was also estimated for
the assessment of the cumulative effect of IL-2 on plasma
nitrate +nitrite levels.
Results
Data were collected from 21 CIVI IL-2 cycles administered to
ten patients (five males, five females; median age 59 years,
range 33-67 years; two affected by metastatic malignant
melanoma and eight suffering from advanced renal cell
carcinoma). Three patients were examined for one cycle,
five patients were examined for two subsequent cycles, two
patients for three and five subsequent cycles respectively.
Fourteen IL-2 CIVI cycles were performed with the IL-2 dose
of 18 MIU m-2 day-1, while seven cycles were administered
at half-dose IL-2 (i.e. 9 MIU m-2 day-'). Reasons for
administering half-dose IL-2 were: doubtful positive history
for previous IL-2 cardiotoxicity (one patient, three cycles);
basal cardiac motion abnormalities at echocardiography (one
patient, two cycles); complementary IL-2 treatment after
surgical excision of metastases (one patient, two cycles). In 20
cycles all scheduled plasma nitrate +nitrite determinations
were obtained. In one cycle, administered to a 56-year-old
RCC patient at 18 MIU m-2 day-', a toxic cardiac event
(myocardial ischaemia) occurred after 26 h of CIVI IL-2 and
the cycle was terminated, so the levels of plasma
nitrate+nitrite measured (to,t,) were excluded from statisti-
cal analysis.
Plasma nitrate+nitrite rose significantly during treatment
(P=0.0226 for to vs t3); as far as different dose levels ofIL-2 are
concerned, significant differences were observed only for cyclesNitric oxide and IL-2
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administered at 18 MIU m-2 day-1 (P=0.0329 for to vs t3;
P=0.0354 for to vs t2 vs 14), while a non-significant minimal
increase was noted in cycles at half-dose IL-2 (see Table II).
Plasma nitrate+nitrite changes were determined in multiple
cycles. A trend towards increase of plasma nitrate+nitrite
levels with cumulative dose of IL-2 was observed: linear
regression coefficient r=0.62 (P=0.014) for to; r=0.80
(P=0.0003) for tl; r=0.62 (P=0.013) for t2; r=0.69
(P=0.045) for t3 (see Table III). Moreover, the peak of
plasma nitrate+nitrite was reached more rapidly from the start
of IL-2 infusion in subsequent cycles with respect to the first
cycle: 6/6 IL-2 infusions as first cycle had peak of plasma
nitrate+nitrite at >72 h, while 5/6 IL-2 infusions as second
cycle and 3/3 IL-2 infusions as third cycle showed plasma
nitrate+nitrite peak at <48 h (P= 0.003). During IL-2
administration, arterial pressure (AP) was monitored every
2 h, and all patients experienced hypotension, presumably
related to the vascular leakage syndrome. The mean ofsystolic
AP values obtained at the time ofplasma nitrate +nitrite peak
for each cycle was significantly lower than that observed at to:
119.76+3.66 vs 137.14+2.98 mmHg (P=0.0004). Figure 1
shows the related changes of mean plasmatic nitric oxide and
systolic blood pressure for all cycles.
Considering the whole groups of cycles, IL-2 administra-
tion had to be interrupted in six cases (6/14 in the high-dose
vs 0/7 in the low-dose group, P= 0.040): five interruptions
were due to cardiovascular toxic side-effects (two cases of
grade III hypotension, two ischaemic ECG changes, one
pulmonary oedema). In one case chest pain was complained
of but neither ECG nor cardiac enzymes changed. The two
cases of grade III hypotension occurred in the second and
fourth cycle in the patient with the highest mean and peak
plasma nitrate+ nitrite values (77.35 and 115 ,mol 1-'
respectively vs 55.46 and 93 ,umol 1-1 for the whole group
of remaining patients, P=0.038 for means). In the second
cycle, the plasma nitrate+nitrite value before the hypoten-
sion was 53.6 ymol 1` and the basal value was 39.9 umol 1-'
(34.3% rise from basal value). In the fourth cycle, the plasma
nitrate +nitrite value before the hypotension was
99.6,mol 1` and the basal value was 82.4 4umol 1-1 (20.9%
rise from basal value). No significant differences were found
in the degree of rise in plasma nitrate+nitrite from basal
Table II Plasma nitric oxide (mean+s.e.m. pmol 1-1) during IL-2
intravenous administration
IL-2 18 MIU IL-2 9 MIU
All cycles m-2day-> m-2 day-1
(n =20) (n = 13) (n =7)
to (basal) 52.15+4.76a 52.80+6.23b,c 51.04+7.89
tj 57.76+5.94 59.17+7.92 55.14+9.21
t2 64.68+5.41 69.61 +7.00c 55.52+7.83
t3 67.60+4.85a 71.70+6.37" 59.97+6.84
t4 66.72+5.09 75.74+4.94c 49.97+8.46
t5 65.20+6.48 68.67+7.20 53.66+ 15.09
ap =0.0226 to vs t3 (ANOVA); bp =0.0329 to vs t3 (ANOVA);
cP=0.0354 to vs t2 vs 14 (ANOVA).
value to the time of maximal hypotension between the two
cycles with grade III hypotension and the remaining cycles.
The same patient experienced the above-mentioned chest pain
in the fifth cycle, in conjunction with the highest value of
plasma nitrate+nitrite observed (115 ymol 1-'). The pulmon-
ary oedema was experienced in the last day of the third cycle
in a 63-year-old RCC patient: the mean plasma ni-
trate+nitrite value in that cycle was 52.65 jumol 1-1 and the
plasma nitrate +nitrite level before the event was
51.3 imol 1-'. Ischaemic ECG changes were observed in a
56-year-old RCC patient, as previously mentioned, and in a
33-year-old MM patient, in which a transient creatine kinase
rise was also observed. Plasma nitrate+nitrite level before
the event in the first patient was 34 ,imol 1-, while mean
cycle nitrate+nitrite and plasma nitrate+nitrite level before
the event in the latter patient were 60.35 and 55.8 imol 1-1
respectively. All toxic side-effects fully recovered after
discontinuation of IL-2. It should be mentioned that a
clinical partial response with recalcification of vertebral
metastases was observed in the patient in whom pulmonary
oedema occurred.
Discussion
Nitric oxide is generated from L-arginine by the enzyme NO
synthase. This represents the final metabolic pathway
induced by many cytokines such as IL-2, TNF-ax and
interferon-y, and is an important signaling molecule that
acts on a variety of cell types: it mediates macrophage (Cox
et al., 1992) and natural killer cytotoxic activity (Cifone et
al., 1994), contributes to the balance between T-helper type
1 and 2 cells (Taylor-Robinson et al., 1994) and modulates
neuroendocrine effects such as vasopressin release from the
hypothalamus and the amygdala (Raber et al., 1994).
Among its activities, a special interest has been concerned
on cardiovascular effects: NO is a mediator of vascular
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Figure 1 Changes of plasma nitrate +nitrite and systolic blood
pressure values during IL-2 infusion (values are presented as
mean+s.e.m.).
Table III Progressive increase of plasma nitric oxide levels (mean+s.e.m. /M 1-1) with cumulative dose of
IL-2
Cycle no. I Cycle no. 2 Cycle no. 3 Cycle no.>4 Linear
(n =6) (n =6) (n =3) (n =5) regression
to 32.46+7.34 57.80+9.55 55.53+5.23 62.16+8.07 r=0.62; P=0.014
tj 29.30+5.93 59.44+8.34 62.33+ 5.43 74.94+10.87 r=0.80; P=0.0003
t2 43.38+7.03 60.42+9.23 79.70+ 14.81 76.51+8.59 r=0.62; P=0.014
t3 48.90+9.04 60.22+6.48 75.30+ 15.04 82.92+5.47 r=0.69; P=0.004
t4 52.52+ 13.40 65.00+7.17 70.56+ 11.77 76.45+7.96 r=0.46; P=NS
t5 41.93+ 14.09 69.92+7.95 56.05+ 13.55 82.52+9.81 r=0.56; P=NS
NS, not significant.Nitric oxide and IL-2
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smooth muscle relaxation, is produced in increased amounts
by numerous cell types, particularly endothelial cells, after
exposure to a number of inflammatory cytokines, and it is at
least partly responsible for IL-2 mediated hypotension, as
the haemodynamic effects induced by IL-2 administration
are reserved by NG-methyl-L-arginine, a NO synthesis
inhibitor (Ochoa et al., 1992; Kilbourn et al., 1995).
Moreover, NO has direct effects on myocardium. In an
experimental model, the infusion of a NO donor into the
global coronary arterial bed of the left ventricle (LV)
resulted in a significant reduction in LV peak and end-
systolic pressures, an earlier onset of LV isovolumic
relaxation and increased LV diastolic distensibility (Paulus
et al., 1994). Recently, plasma NO measured as
nitrate +nitrite determination was showed to increase
during CIVI IL-2 at the dose of 18 MIU m-2 day-' for
5 days, reaching maximal concentrations on day 5, and was
related to maximal TNF-a and IFN-y levels (Miles et al.,
1994). Our results are consistent with previous observations:
plasma nitrate+nitrite levels increase during IL-2 infusion in
a dose-dependent pattern, so that only when IL-2 was given
at 18 MIU m-2 day-' a significant nitrate+nitrite elevation
was observed, while a half-dose of IL-2 does not seem to
induce similar nitrate+nitrite changes. Moreover, a cumu-
lative effect of IL-2 was also noted: 3 week interval between
consecutive IL-2 cycles does not terminate the biological
effect of the cytokine, as a trend toward higher plasma
nitrate+nitrite values through subsequent IL-2 cycles was
noted. This may be partly because of the ability of IL-2 to
elicit immunological reactions with secondary cytokine
production. All patients received IFN-a during intervals
between IL-2 cycles: an effect of this biological response
modifier cannot be excluded, although direct correlation
between IFN-a therapy and NO synthase activation has not
been reported.
Cardiovascular side-effects represent a relevant problem to
deal with during i.v. IL-2 treatment, as they cause the
majority of transient or definitive IL-2 interruptions. In our
series of 224 consecutive IL-2 infusions, 78 (34.8%) were
interrupted owing to toxic events. In particular, 21/78
(26.9%) cycles were interrupted because of grade III-IV
hypotension, while 24/78 (30.1%) interruptions were deter-
mined by cardiac events (i.e. myocardial ischaemia;
arrhythmias such as atrial fibrillation, supraventricular
tachyarrhythmias, grade II atrial-ventricular block; myocar-
ditis) (unpublished data). As NO production and release is
involved either in vascular muscle dilation (Moncada et al.,
1991) or in direct myocardial damage (Paulus et al., 1994),
NO plasma concentration might correlate both with vascular
and cardiac toxic events. Moreover, in a subset of 31 cycles in
which echocardiography was routinely performed before and
after each IL-2 infusion, a number of subclinical echocardio-
graphic abnormalities were found, mainly regarding LV
diastolic impairment, possibly suggesting a pathogenetic role
of NO in damaging myocardial tissue (Di Lucca et al., 1995).
In the present study, plasma nitrate+nitrite levels correlate
with hypotension, as already shown (Miles et al., 1994), while
no association was found between plasma nitrate+nitrite
levels and the cardiac toxic events observed (two ischaemic
ECG changes and one cardiogenic pulmonary oedema). This
seems to suggest that NO is not the final mediator of
myocardial damage where cardiac toxicity is concerned.
Alternatively, the local release of NO via the inflammatory
cascade of cytokines initiated by IL-2 might be enough to
determine impairment of ventricular function, without a
release in systemic circulation to levels detectable by plasma
sampling. A more complex and invasive experimental design
(e.g. intra right atrium blood sampling) would be needed to
get full insight into this tissue.
In conclusion, the determination of plasma nitrate+ nitrite
levels during CIVI IL-2 can provide a useful estimate of the
degree of peripheral vascular relaxation and capillary leakage
associated with cytokine action, clinically manifested as
hypotension. A dose-dependent pattern and course-depen-
dent pattern for plasma nitrate+nitrite changes have been
well established. However, isolated cardiac toxicity, which
continues to represent a relevant problem during IL-2
therapy, does not appear to be predicted by plasma
nitrate +nitrite changes. The mechanisms of this therapy-
limiting toxicity require further studies, so that clinicians
could reliably predict and adequately prevent cardiac events
related to IL-2 infusions.
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